Compare Inovio Pharmaceuticals Inc (INO) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Paychex, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Paychex, Inc. trades at $114.3 (market cap $40.98B). The key difference: Paychex, Inc. is far larger — about 459.1× Inovio Pharmaceuticals Inc's market cap, and Paychex, Inc. pays a 4.13% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PAYX | |
|---|---|---|
Market Cap | $89.27M | $40.98B |
Sector | Health | Industrials |
52-Week High | $2.87 | $147.99 |
52-Week Low | $1.05 | $85.57 |
Enterprise Value | $60.28M | $44.47B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Paychex (PAYX) trades at $115.15, up 0.66% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.32 beating expectations of $1.31, and maintains high profitability with a 27.03% net income margin. Recent developments include dividend declarations and positive small business job growth trends.
Outlook remains positive with steady revenue growth and AI expansion driving future performance, though valuation metrics appear elevated with P/E at 23.39. Key risks include macroeconomic sensitivity to small business hiring and competitive pressures. Analyst consensus is mixed with 63.33% hold ratings and a $110 price target slightly below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
